Neumora Therapeutics (NMRA) to Release Quarterly Earnings on Wednesday

Neumora Therapeutics (NASDAQ:NMRA) is expected to be announcing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.23) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.02. On average, analysts expect Neumora Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Neumora Therapeutics Stock Performance

Shares of NASDAQ NMRA opened at $1.61 on Monday. The business has a fifty day simple moving average of $1.64 and a 200 day simple moving average of $2.15. The company has a current ratio of 5.09, a quick ratio of 5.09 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $298.30 million, a price-to-earnings ratio of -1.21 and a beta of 2.75. Neumora Therapeutics has a one year low of $0.83 and a one year high of $3.65.

Wall Street Analyst Weigh In

NMRA has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating on shares of Neumora Therapeutics in a report on Tuesday, July 28th. Royal Bank Of Canada reduced their price objective on shares of Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Needham & Company LLC decreased their target price on shares of Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday, June 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Friday, July 17th. Finally, Mizuho dropped their price target on shares of Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a research report on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $6.57.

Institutional Investors Weigh In On Neumora Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in NMRA. Hsbc Holdings PLC bought a new stake in shares of Neumora Therapeutics in the 4th quarter worth about $27,000. Virtu Financial LLC lifted its holdings in Neumora Therapeutics by 465.7% during the 4th quarter. Virtu Financial LLC now owns 97,408 shares of the company’s stock valued at $174,000 after purchasing an additional 80,189 shares during the last quarter. Invesco Ltd. lifted its holdings in Neumora Therapeutics by 23.8% during the 4th quarter. Invesco Ltd. now owns 227,594 shares of the company’s stock valued at $407,000 after purchasing an additional 43,795 shares during the last quarter. XTX Topco Ltd acquired a new position in Neumora Therapeutics in the fourth quarter valued at about $204,000. Finally, Ikarian Capital LLC boosted its position in Neumora Therapeutics by 10,128.9% in the fourth quarter. Ikarian Capital LLC now owns 1,278,408 shares of the company’s stock valued at $2,288,000 after buying an additional 1,265,910 shares in the last quarter. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.